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Abstract
Background: Data from centralised, population-based statutory cancer registries are generally considered the 'gold
standard' for confirming incident cases of cancer. When these are not available, or more current information is
needed, hospital or other routinely collected population-level data may be feasible alternative sources. We aimed
to determine the validity of various methods using routinely collected administrative health data for ascertaining
incident cases of colorectal or lung cancer in participants from the 45 and Up Study in New South Wales (NSW),
Australia.
Methods: For 266,844 participants in the 45 and Up Study (recruited 2006–2009) ascertainment of incident
colorectal or lung cancers was assessed using diagnosis and treatment records in linked administrative health
datasets (hospital, emergency department, Medicare and pharmaceutical claims, death records). This was compared
with ascertainment via the NSW Cancer Registry (NSWCR, the 'gold standard') for a period for which both data
sources were available for participants.
Results: A total of 2253 colorectal and 1019 lung cancers were recorded for study participants in the NSWCR over
the period 2006–2010. A diagnosis of primary cancer recorded in the statewide Admitted Patient Data Collection
identified the majority of NSWCR colorectal and lung cancers, with sensitivities and positive predictive values (PPV)
of 95% and 91% for colorectal cancer and 81% and 85% for lung cancer, respectively. Using additional information
on lung cancer deaths from death records increased sensitivity to 84% (PPV 83%) for lung cancer, but did not
improve ascertainment of colorectal cancers. Hospital procedure codes for colorectal cancer surgery identified cases
with sensitivity 81% and PPV 54%. No other individual indicator had sensitivity >50% or PPV >65% for either cancer
type and no combination of indicators increased both the sensitivity and PPV above that achieved using the
hospital cancer diagnosis data. All specificities were close to 100%; 95% confidence intervals for sensitivity and PPV
were generally +/−2%.
Conclusions: In NSW, identifying new cases of colorectal and lung cancer from administrative health datasets, such
as hospital records, is a feasible alternative when cancer registry data are not available. However, the strengths and
limitations of the different data sources should be borne in mind.
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Background
Colorectal and lung cancer are two of the most com-
mon cancers, and the most frequent causes of cancer
death in Australia [1]. The burden of these diseases is
significant, both in terms of health expenditure and
morbidity, not only in Australia but in almost all devel-
oped and developing countries [2]. Understanding and
optimising the prevention, pathways to diagnosis and
patterns of care for these two cancer types, as well as
monitoring the effectiveness of cancer control initia-
tives is a national imperative [3].
Prospective linkage of cohort study questionnaire data
to administrative, routinely collected population health
datasets provides an effective method for identification
of health outcomes, such as incident colorectal and lung
cancers. This ascertainment of cancer cases allows for
powerful and highly efficient investigation of the factors
influencing cancer incidence, mortality, treatment and
survival, which are important for research, evaluation
and planning. Such linkage provides almost complete
participant follow-up for health outcomes, without the
cost, time, burden, and inaccuracies of self-report.
For cancer outcomes, the New South Wales Cancer
Registry (NSWCR; a state-based statutory cancer registry)
is the ‘gold standard’ for identifying cancer cases in NSW,
Australia’s most populous state. The extensive ascertain-
ment and quality assurance processes underpinning the
NSWCR data mean that these data may not be released
until several years after cancers are diagnosed, so study
power may be reduced and contemporary analyses of fac-
tors influencing cancer diagnosis or outcomes may be
more difficult to conduct. Identifying cancer cases via 'sur-
rogate' indicators in other health databases, such as hos-
pital records, which often are more contemporaneous,
may provide a valid substitute for ascertaining certain
types of incident cancers [4]. A large proportion of people
with colorectal or lung cancer are hospitalised, either for
treatment or because of medical complications, making it
a potentially viable option to identify them in hospital re-
cords [5–7]. In a previous report, Kemp, et al. demon-
strated high specificity and sensitivity for detecting
invasive breast cancer using routinely reported hospital re-
cords in NSW [4]. However no previous study in Australia
has investigated the use of this approach for any other
cancer type.
Our objective was, therefore, to use a large-scale
population-based Australian cohort study (the 45 and
Up Study [8]) linked to a range of administrative health
datasets including the NSWCR, to develop and investi-
gate methods for identifying cases of colorectal and
lung cancer up to the most recent date possible. Our
specific aims were to use the 45 and Up Study cohort
to: 1) devise algorithms for identifying incident cases of
colorectal and lung cancer using non-NSWCR datasets;
2) validate these algorithms against the ‘gold standard’
NSWCR dataset from 2006 to 2010 (i.e. a time period
in which complete data were available for both the
NSWCR ‘gold standard’ and the other health datasets)
to determine the optimal algorithm; and 3) identify new
cases of colorectal and lung cancer in non-NSWCR
datasets from 2011 onwards. Exploratory analyses ex-
amined the validity of hospital data for the ascertain-
ment of other cancer types, including prostate cancer,
breast cancer and melanoma.
Methods
Study sample
The Sax Institute’s 45 and Up Study in NSW, Australia,
is a prospective cohort study of healthy ageing in which
more than 266,000 participants consented for ongoing
linkage of individual self-reported data to data from their
medical records [8]. Eligible participants are men and
women aged 45 years and over, randomly sampled from
the Medicare enrolment database of the Department of
Human Services (formerly Medicare Australia), which
provides near complete coverage of the population.
Individuals joined the study by completing a postal
questionnaire (baseline questionnaires were distributed
2006–2009) and giving informed consent for linkage of
their data to population health databases. People aged
80 years and over and those living in regional and re-
mote areas were oversampled by a factor of 2. The study
methods and a characterisation of the cohort are de-
scribed in detail elsewhere [8, 9]. Participants aged less
than 45 years at baseline and those with irreconcilable
information in their linked records (e.g. multiple hospital
admissions after date of death) were excluded.
Ethical approval for the 45 and Up Study as a whole
was provided by the University of New South Wales
Human Research Ethics Committee and specifically for
this analysis by the NSW Population and Health Services
Research Ethics Committee.
Data sources and probabilistic record linkage
Questionnaire data from study participants were linked
probabilistically to a number of population-wide health
databases (Fig. 1): (1) NSW Admitted Patient Data Collec-
tion (APDC; July 2001–June 2014), which is a complete
census of all public and private hospital admissions in
NSW. Hospital medical coders abstract individual patient
information from medical records following the patient’s
discharge from hospital. This includes dates of admission
and separation, procedures carried out and diagnoses re-
lating to the hospital episode; (2) Emergency Department
Data Collection (EDDC; January 2005–December 2014),
which records presentations to emergency departments in
most public hospitals across NSW; (3) NSW Cancer
Registry (NSWCR; January 1994–December 2010), which
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records details of all notifications of primary cancer diag-
noses for residents of NSW; (4) Australian Coordinating
Registry Cause of Death Unit Record File (COD-URF;
January 2006–December 2012), which contains informa-
tion about causes of death in Australia, taken from death
records.
These datasets were probabilistically linked by the
Centre for Health Record Linkage [10] using a best prac-
tice approach to linkage while preserving privacy [11] and
the open source probabilistic record linkage software
ChoiceMaker. The probabilistic matching process is
known to be highly accurate (false-positive and false-
negative rates <0.5%) and a more detailed description of
the linkage process has been provided elsewhere [12].
Medication use and subsidised outpatient and medical ser-
vices from June 2004 to December 2014 were available for
all study participants from the Department of Human Ser-
vices via linkage to the Pharmaceutical Benefits Scheme
(PBS; a database of all government subsidised prescription
pharmaceuticals) and the Medicare Benefits Schedule
(MBS; a database of the Medicare services subsidised by
the Australian government and available to all Australian
residents) using a unique identifier that was provided to
the Department of Human Services by the Sax Institute.
Ascertainment of cancer cases in the NSWCR
Colorectal and lung cancers were defined as primary in-
vasive cancers that were diagnosed according to the
NSWCR between January 1994 and December 2010.
Using the 10th revision of the International Classifica-
tion of Disease, Australian Modification (ICD10-AM),
colorectal cancers were coded as C18-C20 and lung can-
cers as C34. Month and year of diagnosis were supplied,
but not the day of diagnosis.
Ascertainment of cancer cases in other health datasets
The possible indicators for identifying new cases of
colorectal and lung cancer in each dataset are listed in
Table 1. Hospital discharge diagnosis data from the
APDC comprised up to 55 diagnosis fields for each ad-
mission, coded according to ICD10-AM. The diagnosis
information included the reason for the hospital admis-
sion or factors relating to the hospital stay, which could
include a new/recent diagnosis of cancer (referred to
here as a “hospital cancer diagnosis record”, using
codes C18-C20 for colorectal cancer and C34 for lung
cancer) or a record indicating a personal history of the
disease (not a new/recent diagnosis of cancer, using code
Z85.0 for colorectal cancer and Z85.1 for lung cancer).
Secondary colorectal or lung cancers, such as brain cancer
that had metastasised to the lungs, were not included in
this analysis. EDDC records had one diagnosis for each
presentation, coded according to either the ICD10-AM,
ICD 9th revision (ICD9) or SNOMED classification
system.
Colorectal and lung cancer treatments were captured in
the APDC where up to 50 procedure codes could be re-
corded at each admission and by a single item code per
claim in the MBS (see Additional file 1 for details of diag-
nosis, procedure and item codes used). Procedures in the
APDC were coded using the Australian Classification of
Health Interventions, which is used in conjunction with
ICD10-AM. Chemotherapy medicines listed on the PBS
for colorectal cancer included fluorouracil and oxaliplatin,
while for lung cancer the medicines included carboplatin,
cisplatin and docetaxel (see Additional file 1 for details).
The included treatments were indicated for colorectal and
lung cancers but were not necessarily exclusive to these
conditions. The COD-URF was used to identify deaths
with primary colorectal or lung cancer (not secondary
colorectal or lung cancer) as the main cause of death or
one of up to 20 contributing causes of death.
Statistical methods
Sensitivity, specificity and the positive predictive value
(PPV) of ascertaining cases of cancer for February 2006
to December 2010 (the period when data were available
for all datasets) in non-NSWCR datasets compared to
45 and Up Study
Feb 2006 - Dec 2009
Hospital records (Admitted Patient Data Collection [APDC]) Jul 2001 - Jun 2014
Cancer registrations (NSWCR) Jan 1994 - Dec 2010
Emergency Department Data Collection (EDDC) Jan 2005 - Dec 2014
Death records (COD-URF) Feb 2006 - Dec 2012
2001 … 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Medicare claims data (MBS / PBS) Jun 2004 - Dec 2014
Fig. 1 Health-related data collections used in the study and dates of available data. APDC: Admitted Patient Data Collection; COD-URF: Cause Of
Death Unit Record File; EDDC: Emergency Department Data Collection; MBS: Medicare Benefits Schedule; NSWCR: New South Wales Cancer Regis-
try; PBS: Pharmaceutical Benefits Scheme
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the ‘gold standard’ NSWCR were calculated separately
for colorectal and lung cancer. A true positive was de-
fined as a colorectal/lung cancer that was first identified
in a non-NSWCR dataset up to 12 months before or
after a NSWCR-recorded colorectal/lung cancer diagno-
sis date, where the date for the non-NSWCR diagnosis
was the first date of its occurrence in the dataset (e.g.
hospital admission date as opposed to the discharge
date, ED presentation date or service/supply date). A
true negative was defined as the absence of a derived in-
dicator of colorectal/lung cancer in a non-NSWCR data-
set and the absence of a colorectal/lung cancer record in
the NSWCR. Sensitivity, specificity and PPV were calcu-
lated using the NSWCR as the reference standard. Sensi-
tivity was calculated as the proportion of all cases in the
NSWCR who were true positives in the relevant non-
NSWCR dataset. Specificity was calculated as the pro-
portion of all people who were not identified as cases in
the NSWCR who were true negatives in the relevant
non-NSWCR dataset. PPV was defined as the propor-
tion of all cases identified in the relevant non-NSWCR
dataset who were true positives in that non-NSWCR
dataset.
Sensitivity, specificity and PPV were compared for
algorithms using different combinations of colorectal/
lung cancer indicators from non-NSWCR datasets to de-
termine the optimal algorithm for case ascertainment
for each cancer type. The main focus of the paper was
estimating sensitivity, specificity and PPV based on true
positives being within +/− 12 months, however we also
estimated these measures based on true positives being
within +/− 3 months. After identifying the optimal algo-
rithm we also assessed the sensitivity, specificity and
PPV for different follow-up periods, using data prior to
2006 where available. Using the optimal algorithm, colo-
rectal and lung cancer cases were then identified in non-
NSWCR datasets beyond 2010 to determine how use of
the algorithm might impact the number of cases (and
Table 1 Validity of potential indicators for lung and colorectal cancer compared with the NSW Cancer Registry, February 2006 to
December 2010
Source Colorectal cancer
(No. cases in NSWCR: 2253)
Lung cancer
(No. cases in NSWCR: 1019)
No. cases
identified




APDC diagnosis of cancer 2338 91% 95% 99.9% 968 85% 81% 100.0%
APDC diagnosis of history of primary cancer 2487 24% 26% 99.5% 166 23% 4% 100.0%
APDC surgical resection 3376 54% 81% 99.4% 400 60% 23% 99.9%
APDC chemotherapy 1333 12% 7% 99.6% 1333 6% 7% 99.5%
APDC radiotherapy 456 4% 1% 99.8% 456 14% 6% 99.9%
EDDC diagnosis of primary cancer 27 44% 1% 100.0% 56 50% 3% 100.0%
MBS surgical resection 1793 59% 47% 99.7% 310 45% 14% 99.9%
MBS radiotherapy item 6051 3% 9% 97.8% 6051 5% 33% 97.9%
MBS chemotherapy item 4940 12% 27% 98.4% 4940 7% 35% 98.3%
PBS chemotherapy drug item 1663 46% 34% 99.7% 2082 14% 28% 99.3%
COD-URF death record with primary cancer type 364 36% 6% 99.9% 609 62% 37% 100.0%
Combinations of indicators
APDC cancer diagnosis or history of cancer 3254 65% 94% 99.6% 1016 81% 81% 99.9%
APDC cancer diagnosis or surgery 3738 57% 95% 99.4% 1119 74% 81% 99.9%
APDC cancer diagnosis and surgery 1933 94% 80% 100.0% 246 96% 23% 100.0%
APDC cancer diagnosis and APDC chemotherapy or radiotherapy 201 83% 7% 100.0% 145 83% 12% 100.0%
APDC or EDDC diagnosis of primary cancer 2345 91% 95% 99.9% 980 84% 81% 100.0%
MBS or PBS chemotherapy or radiotherapy 9144 9% 38% 96.9% 9178 5% 49% 96.8%
APDC cancer diagnosis and MBS/PBS chemotherapy or
radiotherapy
963 86% 37% 100.0% 526 79% 41% 100.0%
APDC cancer diagnosis and COD-URF primary cancer 242 52% 6% 100.0% 483 71% 34% 100.0%
APDC cancer diagnosis or COD-URF primary cancer 2370 90% 95% 99.9% 1042 83% 84% 99.9%
APDC Admitted Patient Data Collection, COD-URF Cause Of Death Unit Record File, EDDC Emergency Department Data Collection, MBS Medicare Benefits
Schedule, NSWCR New South Wales Cancer Registry, PBS Pharmaceutical Benefits Scheme, PPV Positive predictive value
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hence statistical power) for further analysis of risk fac-
tors, health services utilisation, and cancer outcomes. In
order to investigate whether there were any systematic
biases underpinning the ‘missed’ and ‘extra’ incident can-
cer cases in the hospital records, we further assessed
these cases in relation to their cancer stage, area-level
socio-economic disadvantage, geographic area of resi-
dence and vital status and timing of death. Preliminary
testing was also carried out for other cancer types, using
the most common incident (post-baseline) cancer types
in the NSWCR for study participants (Table 2).
Results
There were 266,844 participants recruited to the 45 and
Up Study in 2006–2009. We excluded 50 people (0.02%)
who were either aged less than 45 years at baseline or
who had linked health-related data that could not be
reconciled (e.g. multiple hospital admissions after date
of death), leaving 266,794 eligible participants.
There were 2253 people with a diagnosis of colorectal
cancer and 1019 with lung cancer recorded in the
NSWCR over the period February 2006–December 2010.
This is the period when data were available from the
NSWCR and all of the other administrative data collec-
tions (Fig. 1). These cancers were newly diagnosed during
that period, but were not necessarily diagnosed after the
baseline questionnaire.
Comparison of potential surrogate indicators for cancer
Table 1 shows the validity of individual indicators for
colorectal and lung cancers in the non-NSWCR data-
sets. Having a hospital diagnosis code for the primary
cancer type (colorectal or lung) was by far the best indi-
vidual indicator for both cancer types, with sensitivity
and PPV of 95% and 91% respectively for colorectal
cancer and 81% and 85% respectively for lung cancer.
The 95% confidence intervals for these measures were
within +/− 1.2% for colorectal cancer and within +/−
2.4% for lung cancer. Hospital records for colorectal
cancer surgical procedures identified cases with 81%
sensitivity and 54% PPV, but no other individual marker
had >50% sensitivity or >65% PPV for colorectal or lung
cancer (Table 1). The specificities for each of the indi-
vidual indicators and combinations of indicators were
at least 98%, with most being >99.8% and all 95% confi-
dence intervals for specificity were at least 96% to at
most 100%. The results for hospital cancer diagnosis
records were very similar when the NSWCR cancers
were restricted to those diagnosed after the baseline
questionnaire.
Sensitivity for lung cancer increased from 81% using a
hospital cancer diagnosis, to 84% using the combination
of a hospital cancer diagnosis and/or a death record
where lung cancer was recorded as a cause of death.
However the PPV decreased slightly from 85% (hospital
cancer diagnosis only) to 83% (hospital cancer diagnosis
and/or death record). The inclusion of death records for
colorectal cancer did not improve identification of colo-
rectal cancers, nor did any combination of indicators in-
crease both the sensitivity and PPV above that obtained
using the hospital cancer diagnosis for either cancer type
(Table 1). Some combinations, for example a hospital
cancer diagnosis plus a surgical resection record, had
slightly higher PPV (94% for colorectal cancer) but sub-
stantially lower sensitivity (80%). The death records were
available to December 2012, compared to June 2014 for
the hospital records, so using the combination of hos-
pital and death records beyond the NSWCR coverage
would also introduce complications due to differing data
availability. Based on these results, we considered the
hospital cancer diagnosis records to be the optimal ‘sur-
rogate’ for identifying new colorectal and lung cancers.
The remaining analysis focused on this data source.
Indicators based on hospital cancer diagnoses
When true positive cases were restricted to those with
a hospital cancer diagnosis up to 3 months before or
after the NSWCR diagnosis date, the sensitivity and
PPV of a hospital colorectal cancer diagnosis both de-
creased by 1% to 94% and 90% respectively. For lung
cancer, the sensitivity and PPV of a hospital cancer
diagnosis dropped from 81% to 72% and from 85% to
76% respectively. Hospital cancer diagnoses first identi-
fied 83% of the NSWCR colorectal cancers and 47% of
lung cancers in the same month as the NSWCR diag-
nosis date. For both cancer types around 2–3% of cases
Table 2 Validity of APDC cancer diagnoses compared with the
NSW Cancer Registry for selected cancer types, July 2001 to
December 2010





Bladder 523 1253 35% 84% 99.7%
Breast 4172 4376 86% 90% 99.8%
Colorectal 3597 3747 91% 95% 99.9%
Kidney 575 616 85% 91% 100.0%
Lung 1225 1151 86% 81% 100.0%
Melanoma 3748 2459 71% 47% 99.8%
Non-Hodgkin
Lymphoma
1003 1080 71% 76% 99.9%
Pancreatic 271 283 81% 84% 100.0%
Prostate 7256 6401 86% 76% 99.7%
Stomach 282 314 78% 87% 100.0%
Unknown primary 306 659 29% 62% 99.8%
Uterine 543 535 93% 92% 100.0%
APDC Admitted Patient Data Collection, NSWCR New South Wales Cancer
Registry, PPV Positive predictive value
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were first identified from a hospital admission in the
month prior to the month of diagnosis in the NSWCR,
with very few cases (<5) identified earlier than 1 month
prior to the NSWCR diagnosis date. As shown in Fig. 2,
the majority of cancers were identified in the same
month or the initial months after the NSWCR diagno-
sis date (the 2–3% in the month prior to the NSWCR
date are not shown).
Restricting the comparison to the NSWCR and hos-
pital cancer diagnosis records, there was a 9.5-year
period of overlap between the datasets where we could
compare diagnoses (July 2001–December 2010).
Defining true positive cases as those up to 12 months
before or after the NSWCR diagnosis date, the results
were very similar to those for the period February
2006–December 2010, with sensitivity and PPV of 95%
and 91% respectively for colorectal cancer (3597
NSWCR cases) and 81% and 86% for lung cancer
(1225 NSWCR cases) (Table 2).
Further investigation of ‘missed’ and ‘extra’ cancer
diagnoses in the inpatient hospital data
Of the 3597 colorectal cancer cases in the NSWCR, the
APDC did not identify 195 (5%) within 12 months of the
NSWCR diagnosis date. Of these, 24 were identified in
the APDC after >12 months or after December 2010 (to
June 2014), while seven died from colorectal cancer
within 12 months. Of the remaining 136 cases, around
half lived in areas near the border of another state or
territory, so they may have been hospitalised interstate
and these are not captured in the study datasets. The
NSWCR cases who were not identified in the APDC
more commonly had “unknown” spread of disease at
diagnosis recorded in the NSWCR (33% vs 7% of those
who were in the APDC) but the proportions with dis-
tant metastases recorded were similar (9% vs 10%) and
there was little difference by age at diagnosis in the
NSWCR (median 68 vs 69). The APDC also identified
332 colorectal cancer cases who were not in the
NSWCR during July 2001–December 2010. Of these,
123 (37%) were recorded in the NSWCR prior to July
2001 (from January 1994). Comparing cases identified
in the APDC over the 9.5-year period to all cases re-
corded in the NSWCR without considering the dates of
these records, the APDC had a PPV of 94%.
The sensitivity with which the hospital cancer diagno-
ses identified NSWCR lung cancer cases for the period
July 2001 to December 2010 (81%) increased to 85% if
we included cases identified in the APDC >12 months
after the date of diagnosis in the NSWCR. If we also in-
cluded APDC cases first identified after December
2010, the sensitivity increased to 91%. Lung cancer
death records identified a further 4% of the NSWCR
cases. The PPV (86%) increased to 90% if we included
cases identified in the APDC >12 months after the date
of diagnosis in the NSWCR and then to 93% if we in-
cluded NSWCR cases diagnosed prior to July 2001.
Comparisons were made between the NSWCR lung
cancer cases who were identified in the APDC within
12 months of the NSWCR date of diagnosis (“matches”,
n = 991, 81%) and those who were not (“non-matches”,
n = 234, 19%). The non-matches were more likely to
have “unknown” spread of disease at diagnosis recorded
in the NSWCR (45% of non-matches vs 13% of
matches), were more commonly from non-metropolitan
areas (56% of non-matches vs 45% of matches) or lower
Fig. 2 Sensitivity and PPV of hospital diagnosis records after the NSW Cancer Registry diagnosis date, February 2006 to December 2010. APDC:
Admitted Patient Data Collection; NSWCR: New South Wales Cancer Registry; PPV: Positive predictive value. Does not include cancers identified
from the APDC prior to the NSWCR diagnosis date (3% of colorectal cancers, 2% of lung cancers)
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socio-economic areas (60% of non-matches were from
the two most disadvantaged quintiles vs 50% of matches)
and were slightly older at diagnosis according to the
NSWCR (median 73 years [inter-quartile range 65–81]
for non-matches vs 71 [63–79] for matches). The non-
matches were more commonly from areas near the
border of another state or territory (21% vs 8% of
matches), so they may have been hospitalised interstate
and these are not captured in the study datasets.
Of the 234 non-matches, 19 (8%) died within 1 month
of the date of diagnosis recorded in the NSWCR (16
were identified using lung cancer death records) and of
these, 13 did not have a hospital admission during or
after the month of diagnosis. The inclusion of lung can-
cer death records increased the sensitivity of identifica-
tion by 3% but reduced the PPV by 2%. This reduction
was due to 37 people having a lung cancer death record
during July 2001–December 2010 but who did not have
a lung cancer diagnosis recorded in the NSWCR during
that time. Based on all of the available data for these 37
people, 10 had a diagnosis of lung cancer recorded in
the NSWCR prior to July 2001 or data suggesting they
may have had lung cancer that was not captured in the
available NSWCR dataset (e.g. pre-1994 or false-negative
linkage), 13 were potentially secondary lung cancers and
14 may have had some other form of lung disease.
Impact of using inpatient hospital data on the numbers
of incident cases available for other analyses
There were 1319 participants with incident colorectal
cancer (diagnosed after joining the study) recorded in
the NSWCR to December 2010. Using cases first iden-
tified by an APDC diagnosis after December 2010
added 1549 colorectal cancer cases up to June 2014, an
increase of 117%.
There were 795 participants with incident lung can-
cer recorded in the NSWCR to December 2010 and the
APDC diagnoses added a further 912 cancer cases to
June 2014, an increase of 115%. Also including cases
identified from cause of death on death records added a
further 51 lung cancer cases, although COD-URF re-
cords were only available to December 2012.
Exploratory analysis for other cancer types
Given our finding that the diagnosis codes in the APDC
were the optimal ‘surrogate’ method for identifying
colorectal and lung cancer types, we also compared
cancer diagnoses in the APDC with NSWCR records
for several other common cancer types (Table 2). The
results show substantial variation by cancer type, with
sensitivities ranging from 47% for melanoma to 92% for
uterine cancer. Lower sensitivities were observed for
cancers where there is less inpatient treatment required
(e.g. melanoma 47%, prostate 76%) and lower PPV for
cancer of unknown primary (29%) where there is less
certainty about the cancer type – 81% of unknown pri-
mary cases according to the APDC also had another
primary cancer type recorded in the APDC. There was
also lower PPV for bladder cancer (35%), where many
cases have long survival and regular inpatient follow-up
(e.g. cystoscopy), so the hospital cancer diagnosis was
identifying a cancer diagnosed several years earlier and
not a new case, or it might be an in situ or non-
invasive case as these are not recorded in the NSWCR
[13]. For some cancer types where the sensitivity was
lower there may be other health-related records that
could help identify cases, such as Medicare records of
outpatient excision biopsies for localised melanoma
cases, but a detailed investigation of the relevant data
sources for this and the other cancer types is beyond
the scope of the current analysis.
Discussion
In this analysis of more than 266,000 individuals with
follow-up of almost 5 years, we found that hospital diag-
noses of colorectal cancer can be used to reliably identify
and/or rule out incident cases in the absence of cancer
registry data. Hospital diagnoses of lung cancer were not
as comprehensive or timely as those for colorectal can-
cer, but still provide a reasonable indicator for incident
lung cancers. However, ascertainment of lung cancer
diagnosis can be improved via the use of lung cancer
death records.
Our results for lung and colorectal cancer broadly
concur with a previous study of breast cancer in 45
and Up Study participants. Kemp et al. reported that
APDC diagnosis codes identified incident breast can-
cers with 86% sensitivity and 86% PPV in 2004–2008
[4]. In our analysis of breast cancer, PPV was 86% and
sensitivity was 90%. Restricting to female cases diag-
nosed in 2004–2008 made no material difference to
our results, which are comparable to the findings of
Kemp et al. The improved sensitivity in our analysis
can be explained because Kemp et al. used a 3 month
window for identification of true positives and only in-
cluded the principal diagnosis code at each hospital
admission, whereas we used a 12 month window and
included all diagnoses recorded at each admission.
The higher sensitivity and unchanged PPV suggests
that the latter is the optimal algorithm. In our study,
we have built on the work of Kemp et al. to show that
other common cancer types (colorectal, lung) are also
amenable to the use of surrogate outcome markers of
diagnosis in routinely collected hospital data. How-
ever, we have also shown in exploratory analysis that
not all cancer types are necessarily amenable to this
approach, especially if treatment does not routinely
occur on an in-patient basis.
Goldsbury et al. BMC Medical Informatics and Decision Making  (2017) 17:23 Page 7 of 10
Colorectal cancers
We found that there was very high validity for hospital
diagnosis records for identifying colorectal cancer, which
is likely to be driven by the high surgery/treatment rates
within a short period after diagnosis for this cancer type.
In contrast, previous studies have found that around
one-third of lung cancer cases in NSW do not receive
cancer-specific treatment [14] so there are fewer oppor-
tunities to be identified with a diagnosis of lung cancer
in hospital records. Nevertheless, many patients with
lung cancer are hospitalised for complications from out-
patient services such as radiotherapy, and complications
from lung cancer itself, which may explain the >80%
sensitivity based on a diagnosis recorded in the APDC in
our study.
Lung cancers
We found that ascertainment of lung cancer diagnosis
can be improved via the use of lung cancer death re-
cords for this low survival disease. It should, however, be
borne in mind that such a strategy will preferentially
identify fatal lung cancers over non-fatal cancers, so this
may not be an appropriate ‘surrogate’ diagnostic marker
for lung cancer for all analyses. The inclusion of death
records improved the sensitivity with which lung cancer
was identified, but led to a slight reduction in PPV. The
death records often identified people who died shortly
after being diagnosed and who did not have a long
period of time to use health services and therefore had
less chance of being identified in the hospital data. The
reduction in PPV caused by the inclusion of death
records was partly due to the introduction of people
who died from cancer but who were diagnosed in the
NSWCR before the study period, along with the inclu-
sion of people who most likely had secondary lung can-
cer metastasised from another primary site or who had
other lung disease but were classified as having primary
lung cancer on their death certificate.
Limitations
One limitation of our analysis is that although it is
population-based, the 45 and Up Study is not strictly
representative of the general population [9], with those
in marginalised groups less likely to participate in stud-
ies of this type. For that reason, hospital data might not
be as sensitive for population-wide identification of lung
cancer as for other cancer types, given that socio-
economic differences exist in smoking rates and in pat-
terns of lung cancer care [6]. However, using an available
dataset containing all NSWCR records for 2001–2009
and their hospital records for 2000–2011, we ran the
same analysis using hospital diagnosis records for the
whole NSW population and obtained similar estimates
for sensitivity for colorectal and lung cancers (data not
shown). Also, the results reflect the data for the study
period and might not be representative of later time pe-
riods. The results also included cancers diagnosed prior
to entry into the 45 and Up Study and so might not be
representative of future incident cancers, but the results
were very similar when only post-baseline cancers were
included. The narrow confidence intervals for sensitivity,
PPV and specificity due to the very large cohort and
numbers of cases are strengths of the study, but it is also
a reflection of the precision of the estimates and not ne-
cessarily their accuracy, as other statistical uncertainty
cannot be excluded.
There are also some limitations to the suggested sur-
rogate markers for incident cancers. The hospital data
do not include information about disease stage or the
actual date of diagnosis, which are often important data
items required for cancer-related studies such as asses-
sing the appropriateness or timeliness of treatment. In
NSW, pathology is performed through a mix of private
and public hospital laboratories, with no one pathology
database covering the entire population, so detailed
individual-level pathology data beyond those included in
cancer registry data were not available. We also did
some preliminary investigating of cancer site/location re-
corded in the hospital records (data not shown) and they
often varied and were different to those recorded in the
cancer registry data, such as the recording of rectosig-
moid cancer as rectal cancer or vice versa. However,
hospital data can be used to identify important health-
related information that is not available from cancer
registries, such as the presence of various comorbid con-
ditions over time.
The surrogate indicators for cancer, particularly for
lung cancer, tended to lag behind the actual diagnosis
date, although around three-quarters were identified up
to 3 months before or after the NSWCR recorded date
of diagnosis. Using these sources would result in a small
dip in the number of cases in the months after the can-
cer registry data ends, due to the surrogate indicators
identifying cases already covered by the final cancer
registry data, but it would then return to around the ex-
pected level. The time lag might be important if trying
to assess a relatively short time-related factor such as
the timeliness of treatment after diagnosis or short-term
survival, but for overall incidence it is a reasonable
measure. There were cases who were not identified
using the hospital records, in particular for lung cancer.
Using hospital records alone will miss a small proportion
of new cases, and they tend to be the people with less
health system contact, such as those with unknown dis-
ease stage or from non-metropolitan areas. This also
suggests that if hospital data are used to calculate inci-
dence, they will give a slight underestimate and could at-
tenuate differences between cancer cases and non-cases
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in analyses of risk factors for cancer. However this re-
lates to a relatively small proportion of the overall num-
ber of cases. The criteria used to assess the validity of
the surrogate indicator algorithms are not perfect, par-
ticularly for people diagnosed at the start/end of the
study period. For example, someone diagnosed in the
NSWCR in December 2010 and in the APDC in January
2011 would be considered a ‘false negative’ in the APDC
due to the study period date cut-off. However we believe
that overall the criteria used provide a strong and object-
ive measure of validity for comparisons.
Furthermore, there are some limitations relating to the
study we have undertaken. The primary purposes of the
non-cancer registry data sources do not include cancer
identification or recording, so they should be used for
this purpose with caution. It is also possible that the col-
lection of hospital data might change in future and this
could impact upon their validity for identifying incident
cancers. There is a small chance of false negative or false
positive linkage, which can have an impact when there is
a relatively small proportion of cases. Finally, the
NSWCR data for 2011 and COD-URF data for 2013 be-
came available as we were completing this study (in
2016), but we have not yet gained access to these data to
allow for further analysis.
In this analysis of specific cancer types, we found that
an algorithm based on hospital records, rather than
emergency department records or Medicare claims, was
the most accessible, practical and valid method for as-
certaining cancer diagnosis. The EDDC is a rich and
useful dataset in its own right, but it does not appear to
contribute to the identification of cancer cases. The
EDDC data custodian warns against the use of diagno-
sis fields in the EDDC for analytical purposes, as only
one diagnosis is recorded per presentation and it is not
coded consistently across all EDs in the state [10]. Fur-
thermore, the EDDC did not capture all EDs in the
state throughout the study period. It covered around
80% of ED presentations in 2007, with coverage con-
tinuing to steadily increase since 2005 [10]. Despite
these limitations, the EDDC still provides powerful in-
formation about an important part of patient care.
Similarly there was a great deal of information gained
from the claims records in the MBS and PBS. The data
identified many thousands of people who had cancer
treatment and provide an excellent insight into patient
care, but the recorded items may not be specific to can-
cer types (e.g. chemotherapy medicines such as doce-
taxel can be used for several different cancer types) so
by themselves they may not be useful as surrogate indi-
cators for these specific cancers. Future work, however,
will explore methods for overcoming such issues via
the use of probabilistic algorithmic approaches using
the rich information in all of the available datasets.
Implications
For ongoing cohort studies there is great benefit in having
cancer incidence data that are as current as possible,
allowing for more timely and relevant examination of
cancer-related outcomes, as well as a greater number of
cases to increase the power to detect associations. Fur-
thermore, for countries that lack centralised cancer regis-
tries, being able to estimate cancer incidence through
hospital and other medical records is of benefit for re-
search, surveillance and planning purposes.
APDC diagnosis records for colorectal or lung cancer
were adequate for identifying new cases of these cancer
types in this prospective cohort study. Using the APDC
to identify new cases of colorectal and lung cancer pro-
vides more up-to-date cancer incidence data and permits
investigation of a range of topics with greater follow-up
time from entry into the study and higher statistical
power. Using the APDC diagnosis data to the end of the
follow-up period (June 2014) more than doubled the
number of incident cancers since entry into the study
compared to using cancer registry data alone, increasing
the median follow-up time from 2.5 to 6 years and pro-
viding greater power to, for example, detect associations
between risk factors and cancer incidence. Using hos-
pital records, the vast majority of cases in the cohort
were picked up and those who were identified as having
cancer are highly likely to be true cases. The extremely
large cohort provided large numbers of cases and precise
estimates and the use of population-based datasets al-
lows for excellent coverage of the cohort and the condi-
tions of interest.
Conclusions
In conclusion, identifying cases of colorectal and lung
cancer in administrative health datasets, such as hospital
records, may be a feasible alternative to use of cancer
registry data in Australia, provided that the limitations
of such data are carefully borne in mind. We found that
a hospital inpatient diagnosis of colorectal or lung can-
cer is the most valid individual surrogate indicator for
these cancer types and is relatively simple to implement.
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